Tonix reported positive Phase II results for TNX-102 SL (sublingual formulation of cyclobenzaprine) marking the first-ever large multicenter trial for military-related PTSD. The 237-person study compared two dosage levels (2.8mg and 5.6mg) against placebo and found a significant improvement for the 5.6mg dose (p=0.038) in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), the primary endpoint for approval.
25 May 2016
Phase II success in military-related PTSD
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Phase II success in military-related PTSD
- Published:
25 May 2016 -
Author:
Maxim Jacobs -
Pages:
6
Tonix reported positive Phase II results for TNX-102 SL (sublingual formulation of cyclobenzaprine) marking the first-ever large multicenter trial for military-related PTSD. The 237-person study compared two dosage levels (2.8mg and 5.6mg) against placebo and found a significant improvement for the 5.6mg dose (p=0.038) in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), the primary endpoint for approval.